The US Food and Drug Administration’s advisory committee scheduling policy could be updated as part of an ongoing modernization initiative, potentially impacting the number of meetings that could be held.
Kevin Bugin, acting deputy director of operations in the FDA Office of New Drugs, said that because advisory committee meetings...